Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

Inclusion Criteria:

Age ≥18 years
Histologically-confirmed, locally advanced unresectable or metastatic RCC (cohort A) or UC (cohort B).
ECOG performance status of ≤1

Adequate bone marrow function:

Platelet count ≥ 100 × 10^9/L
ANC ≥ 1.0 ×10^9/L
Lymphocyte count ≥ 0.5 ×10^9/L
Willingness to undergo bone marrow aspiration (BMA)

Exclusion Criteria:

Prior hematopoietic stem cell transplantation
Prior radiation to the pelvic region
Use of systemic corticosteroids within 28 days of BMA
History of another primary malignancy that has been diagnosed or required therapy within the past 2 years (except completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site).
Presence of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. If the autoimmune disease has been treated, it must be stable clinically. (Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is not considered an exclusion criterion.)
Pregnant females as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy, obtained within 21 days of BMA
Infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of BMA
Known diagnosis of HIV or CMV infection or active viral hepatitis
Administration of hematopoietic growth factor support within 14 days before bone marrow aspiration
Chemotherapy administration within 28 days of BMA
Unwilling or unable to comply with the protocol
Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the subject.